30 results about "Anorexiants" patented technology

The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and / or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R<1 >and R<2 >have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

Compounds of formula (I) wherein A, B, b, W, X, Y, Z, R1, R2, and R3 have the meanings given in claim 1, pharmaceutical compositions these compounds, and methods of preventing or treating metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes using these compounds.

The present invention relates to the use of a compound of formula (I):or a pharmaceutically acceptable solvate or salt thereof in the preparation of a medicinal product for the prevention and / or the treatment of a disease in which the GLP-1 receptor participates or mediates, such as eating disorders or diseases, for example, obesity, anorexia, lipid dysfunction, diabetes, hyperinsulinism and cardiovascular diseases or metabolic syndrome.

The invention provides unpolished rice and corn mixed child leisure food and a preparation method thereof. Unpolished rice and corn serve as main raw materials, compared with common fine milled rice, the unpolished rice is richer in vitamin, mineral substances and dietary fibers, the nutritional value of the corn is lower than that of other grains, isomaltose oligosaccharides can be extracted from the corn and are the best probiotics which are grains for probiotic bacteria and have close relationship with reproduction of the probiotic bacteria of human bodies, so that intestinal flora are balanced, intestines are healthy, auxiliary materials such as coix seeds, common yam rhizome, hawthorn fruits and mint powder are added, the food is good in taste and rich in nutrients and can improve gastrointestinal functions and enhance appetite after teenagers eat the food serving as a snack, and anorexia of children at the age of 5-12 years is effectively treated.

The invention relates to a spleen invigorating and appetite promoting tablet. The spleen invigorating and appetite promoting tablet is prepared through tabletting a soft material and a flow aid; the soft material is prepared through using 100-160 parts by weight of a raw material concentrate, 10-20 parts by weight of haw powder, 9-11 parts by weight of an auxiliary material zinc gluconate and 25-35 parts by weight of sucrose; the flow aid is magnesium stearate, and the addition mass of magnesium stearate accounts for 0.3-0.7% of the total mass of the raw material concentrate, the haw powder, zinc gluconate and the sucrose powder; and the raw drugs of the concentrate comprise 55-85 parts by weight of haw, 8-12 parts by weight of malt, 9-11 parts by weight of Radish Seed, 4-6 parts by weight of white hyacinth bean and 3-7 parts by weight of dried orange peel. The tablet has the efficacies of food digestion, stomach strengthening, qi rectifying, spleen invigorating and appetite promoting, can effectively alleviate and treat symptoms comprising gastral cavity fullness, food indigestion, spleen-stomach deficiency, appetite loss and the like, and can also prevent the appearance of anorexia.

Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.

Composition and formulations comprising a first agent such as folinic acid, pharmaceutically acceptable salts thereof or mixtures thereof, and a second agent(s) such as analgesics, muscle relaxants, mood disorder agents, anti-inflammatories, anti-migraine agents, anti-emetics, diuretics, high protein composites, and the like. The products are suitable as nociceptics and for the treatment of wasting disorders, bulimia, anorexia nervosa, anxiety, irritability and other symptoms associated with Pre Menstrual Syndrome, as well as for administration either in conjunction with steroids or to compensate adenosine depletion and / or bizarre behavior or aggression common in steroid users.

Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, insulin resistance, lipodystrophy and hypothalamic amenorrhea, anorexia-related infertility, among other diseases and conditions related to leptin deficiency and / or leptin resistance.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.

The present invention relates to (hetero)aryl compounds of general formula I wherein the groups and radicals A, B, Q, W, X, Y, Z, R1, R2, R4a, R4b, R5a, R5b, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

The invention discloses a health-care food for patients with infantile anorexia to eat and a preparation method of the health-care food. The health-care food is prepared from buckwheat, millet, indicarice, traditional Chinese medicine extracts and the like according to the principle of medicated diet. The health-care food has dual functions of foods and medicines, and is mainly used for conditioning, and supplements pharmacology, so toxic and side effects caused by long-term medication are avoided; and the health-care food can eliminate the root and soil of the disease from the aspects of improving the physique of a patient and conditioning the internal environment of the patient, so good health-care effects of strengthening the physique, improving the immunity and assisting in treatmentare achieved. In addition, the health-care food is simple and practicable in preparation process, low in investment, low in cost, applicable to people of all ages, applicable to popularization and transformation and capable of creating higher social value.

The invention relates to a traditional Chinese medicine ointment for treating infantile anorexia, and the traditional Chinese medicine ointment is prepared from the following components: codonopsis pilosula, bighead atractylodes rhizome, rhizoma atractylodis, poria cocos, honey-fried licorice root, Chinese yam, lotus seed, radix bupleuri, rhizoma cimicifugae, fructus amomi, fried fructus aurantii, mangnolia officinalis, cassia twig, astragalus membranaceus, radix saposhnikoviae, pericarpium citri reticulatae, rhizoma pinellinae praeparata, amomum cardamomum, jujube, angelica sinensis, radix paeoniae alba, semen cuscutae, fructus alpiniae oxyphyllae, baked ginger, elecampane, fried malt, fingered citron, smoked plum, schisandra chinensis, scorched hawthorn fruit, fried rice sprout, medicated leaven, ganoderma lucidum, fructus forsythiae, honey, rock candy and donkey-hide gelatin. The traditional Chinese medicine ointment has the effects of improving and even eliminating the infantile anorexia and preventing diseases such as recurrent respiratory tract infection, malnutrition, anemia and rickets accompanied by the infantile anorexia.

A traditional Chinese medicinal preparation for treating children anorexia and a preparation method thereof. The traditional Chinese medicinal preparation is used to treat symptoms such as children apocleisis and enhance digestive function. The traditional Chinese medicinal preparation is prepared by the following raw materials of: by weight, 5-100 parts of jujube, 5-100 parts of Chinese yam, 5-100 parts of sharpleaf galangal fruit, 5-40 parts of haw, 5-20 parts of Poria cocos, 5-40 parts of mushroom and 5-20 parts of orange peel. The preparation provided by the invention has effects of invigorating energy, nourishing yin, invigorating the spleen, benefiting the stomach, removing stagnation and enlivening the spleen, and has a good curative effect of treating children anorexia symptoms such as children's spleen-stomach disharmony, weak spleen and stomach, children's stomach yin deficiency and the like. The raw medicines of the preparation are all vegetation edible and medicinal materials published by Ministry of Public Health, have no toxic and side effect, will not generate toxic intermediates with each other, and can be prepared into dosage forms such as paste and brewing granules which have treatment, nutrition and nourishing effects through processing. The traditional Chinese medicinal preparation has advantages of good taste and strong compliance of children patients, and is applicable to be taken for a long time.

This invention provides a Chinese traditional medicinal composition used for treating the weakening of digestive function. The composition is prepared by using certain ratio of crataegolic, kudzu roots, rose according to a certain processing technology. It has obvious performance in treating the child anorexia shown anorexia and les eating.

The present invention is directed to novel polypeptides NS4 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating body weight disorders (e.g., obesity, cachexia or anorexia) are provided.

The invention discloses a whole-bean rolled candy and a preparation method thereof. The whole-bean rolled candy is a candy prepared by processing soybeans, syrup and egg white as main raw materials. The preparation method comprises the following steps of: processing soybeans; boiling syrup; whipping the egg white; mixing syrup; adding materials; dishing and refrigerating; cutting; and packaging. Compared with the prior art, the whole-bean rolled candy has the advantages that the process is simple, the cost is low, the special nutritional value and unique flavor of soybeans are maintained, thewhole-bean rolled candy can be used as a candy with nutrition and excellent taste, nutrition can be provided for people with hypoglycemia, mental workers and patients with malnutrition or anorexia, and the whole-bean rolled candy can be eaten after the package is opened.

Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.

Disclosed is a CNTF intranasal preparation for treatment of obesity with an absorption enhancer added, improving the bioavailability of biomacromolecular drug nasal administration, wherein a macromolecular protein drug may be delivered into blood, reaching and exceeding the effective injection blood drug concentration. It shows significant weight loss effects on normal mice, diet-induced obesity (DIO) mice, and DIO rat body weight, more effective than subcutaneous administration and positive drugs in the market, in a dose dependent manner. Pharmacodynamic results show that the weight loss stability was significantly better than that of subcutaneous administration, and antibody production was significantly reduced, without causing weight rebound and anorexia reaction. The formulation significantly improves the bioavailability compared to ordinary intranasal formulations, and has a simple preparation process, and stable and controllable quality, and is suitable for industrial production.

The invention belongs to the technical field of health food, and in particular relates to a composition and a compressed candy which are helpful for alleviating chronic fatigue syndrome and anorexia nervosa. The composition comprises the following raw materials and parts by weight: 1-2 parts of bone collagen peptide, 1-2 parts of salina extract, 5-10 parts of grape extract, and 1-2 parts of Cordyceps militaris powder. The invention also provides a compressed candy, which is rich in nutrients such as various enzymes and proteins, and is suitable for people suffering from chronic fatigue syndrome and anorexia nervosa.

The invention relates to a traditional Chinese medicine composition for strengthening spleen and strengthening body resistance for children. The traditional Chinese medicine composition is prepared from the following raw material medicines: a whole placenta, 30-35g of antler tablets, 25-30g of eggshell powder, 20-30g of endothelium corneum gigeriae galli, 25-35g of red ginseng, 25-30g of pseudo-ginseng, 25-35g of fried malt, 30-40g of fried rice sprout, 45-55g of fried maggot, 45-55g of fried dried orange peel, 50-60g of fried radix pseudostellariae and 40-50g of Chinese fevervine herb. The traditional Chinese medicine composition is mainly used for treating weakness of spleen and stomach, anorexia, abnormal snoring, hyperactivity, malnutrition, malnutrition and the like of children.

The present invention relates to mammalian mahogany genes, including the human mahogany gene, which are novel genes involved in the control of mammalian body weight. The invention encompasses nucleotide sequences of the mahogany gene, host cell expression systems of the mahogany gene, and hosts which have been transformed by these expression systems, including transgenic animals. The invention also encompasses novel mahogany gene products, including mahogany proteins, polypeptides and peptides containing amino acid sequences mahogany proteins, fusion proteins of mahogany proteins polypeptides and peptides, and antibodies directed against such mahogany gene products. The present invention also relates to methods and compositions for the diagnosis and treatment of mammalian body weight disorders, including obesity, cachexia, and anorexia, and for the identification of subjects susceptible to such disorders. Further, the invention relates to methods of using the mahogany gene and gene products of the invention for the identification of compounds which modulate the expression of the mahogany gene and / or the activity of the mahogany gene product. Such compounds can be useful as therapeutic agents in the treatment of mammalian body weight disorders, including obesity, cachexia, and anorexia.